Trend analysis as per recent USFDA guideline [Bioanalytics]

posted by dshah – India, 2020-08-01 07:32 (80 d 02:33 ago) – Posting: # 21815
Views: 2,049

Dear All!

If we consider the recent FDA guideline or ICH M10, i believe trend analysis for IS response, CC and QCs is also required. FDA does ask if there is upward or downward trend observed. The important point for SOP of CRO should be - allowed limit for IS response. If this not limited for that 3 subjects, then i believe CRO's practice and SOP needs to be revised.

Regards,
Dshah


Edit: Guidelines linked. [Helmut]

Complete thread:

Activity
 Admin contact
21,165 posts in 4,410 threads, 1,476 registered users;
online 10 (1 registered, 9 guests [including 7 identified bots]).
Forum time: Tuesday 10:05 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5